Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: J Stone who wrote (27767)	2/2/1999 7:01:00 PM
From: Henry Niman	Respond to of 32384

Tamoxifen and taxol are different and have different mechanisms of action. Tamoxifen is a SERM and binds to the estrogen receptor. Taxol binds to microtubules which are involved with maintaining cells shape and cell division. Tamoxifen can cause death (I think through pulmonary embolisms). In the breast cancer prevention trial, those on Tamoxifen had fewer breast cancer deaths, but the number of deaths between Tamoxifen and placebo was about the same due to Tamoxifen side effects.

To: J Stone who wrote (27767)	2/2/1999 9:00:00 PM
From: RXGOLF	Respond to of 32384

Jeff, While I agree with Henry in that toxicity can be severe with tamoxifen, the product literature reads in the first sentence under adverse reactions: "Adverse reactions with Tamoxifen Citrate Tablets are relatively mild and rarely severe enough to require discontinuation of therapy." I believe that hot flashes, nausea, weight loss, and irregular menses are some of the "milder" but more common side effects. IMO there are many patients that would love to have another option for their treatment, but since none are there at this time, we obviously see one reason that the adverse reactions rarely require discontinuation of therapy! Greg